Journal article
Engaging stakeholders and promoting uptake of OMERACT core outcome instrument sets
SR Tunis, LJ Maxwell, ID Graham, BJ Shea, DE Beaton, CO Bingham, P Brooks, PG Conaghan, MA D'Agostino, MP De Wit, L Gossec, LM March, LS Simon, JA Singh, V Strand, GA Wells, P Tugwell
Journal of Rheumatology | J RHEUMATOL PUBL CO | Published : 2017
Abstract
Objective. While there has been substantial progress in the development of core outcomes sets, the degree to which these are used by researchers is variable. We convened a special workshop on knowledge translation at the Outcome Measures in Rheumatology (OMERACT) 2016 with 2 main goals. The first focused on the development of a formal knowledge translation framework and the second on promoting uptake of recommended core outcome domain and instrument sets. Methods.We invited all 189 OMERACT 2016 attendees to the workshop; 86 attended, representing patient research partners (n = 15), healthcare providers/clinician researchers (n = 52), industry (n = 4), regulatory agencies (n = 4), and OMERACT..
View full abstractGrants
Awarded by Horizon Pharmaceuticals
Funding Acknowledgements
IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN # 143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.